View More Recent Stories
-
Piper Sandler Reiterates OW Rating on Cogent (COGT) Ahead of Pivotal Non-AdvSM Data
-
Cogent Biosciences (COGT) Secures up to $400 Million in Non-Dilutive Financing
-
Cogent (COGT) PT Lowered to $12 at H.C. Wainwright
-
Cogent Biosciences (COGT) spreader of 10K contracts of August 5 and 10 calls
-
Scotiabank Starts Cogent (COGT) at Sector Outperform
-
Jefferies Reiterates Buy Rating on Cogent (COGT)
-
Cogent (COGT) PT Lowered to $14 at H.C. Wainwright
-
Cogent Biosciences (COGT) Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Cogent Biosciences (COGT) Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
-
Piper Sandler Reiterates Overweight Rating on Cogent (COGT)
-
Cogent (COGT) PT Lowered to $15 at Needham
-
Cogint (COGT) Misses Q3 EPS by 7c
-
Citi on Cogent (COGT): 'Non Advanced SM Discontinuation Is Old News; Buy on Weakness'
-
H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
-
Cogent Biosciences (COGT) Announces Pipeline Expansion into KRAS and Poster Presentations
-
Cogent (COGT) PT Raised to $15 at Citi
-
Cogent (COGT) PT Raised to $10 at Baird
-
Cogent (COGT) PT Lowered to $17 at H.C. Wainwright
-
Citi Reiterates Buy Rating on Cogent (COGT)
-
Piper Sandler Reiterates Overweight Rating on Cogent (COGT)
-
Cogint (COGT) Misses Q2 EPS by 3c
-
Cogent Biosciences (COGT) Reports Positive FDA Meeting and Alignment on MS2D2
-
Cogent Biosciences (COGT) Announces Additional Data from Part 1 of SUMMIT Trial Evaluating Bezuclastinib
